Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics; SCIEX, a global leader in
life science analytical technologies; and Discovery Life Sciences
(Discovery), a global leader in biomarker development and
biospecimen solutions utilizing proteomic, genomic, cell, and
immunohistochemistry (IHC) technologies, today announced they have
signed an agreement to form the Proteogenomics Consortium, a
collaboration that will enable genomics customers to more easily
add deep, unbiased proteomics data to their discovery,
translational and clinical studies. Through this multi-year effort,
Discovery will establish, expand, and offer deep, unbiased
proteomics capabilities to their existing genomics customers using
the Seer Proteograph Product Suite and the SCIEX ZenoTOF 7600
platform. This will create a capacity for more than one billion
peptides each year to be analyzed and cataloged, allowing the
discovery of new protein variants and novel biomarkers, potentially
leading to therapeutic breakthroughs.
Seer and SCIEX will contribute industry-leading proprietary
proteomics technologies and instrumentation, and Discovery will
provide its significant scale and expertise in genomics services
and biospecimens, to provide services that support population-scale
plasma proteogenomic projects. Seer’s Proteograph Product Suite
includes proprietary engineered nanoparticles, consumables, an
automation instrument, and software that enables deep, unbiased
proteomics studies with an unprecedented combination of speed,
scale, depth, and breadth of data. It accurately surveys thousands
of proteins and millions of peptides with precision. The SCIEX
ZenoTOF 7600 system is a high-resolution, accurate mass system
combining the power of Zeno trap pulsing with electron activated
dissolution (EAD) fragmentation technology to uncover structural
information, previously inaccessible, and drive the limits of
quantification achievable with accurate mass. Discovery will expand
their existing biomarker discovery platform as part of their
proteomics strategy, expanding the technology platforms available
to their worldwide customer base. Their unique service-oriented
scientific team will deliver reliable scientific insight for
proteogenomic studies.
A graphic accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/768575cc-383e-468e-a396-e5d71e472bfb
“This is a highly innovative and novel partnership wherein, for
the first time, three scientific service and technology industry
leaders are dedicating and combining resources at this scale to
advance proteogenomic research. This collaboration will overcome
existing research challenges and accelerate progress in our
understanding of human health and disease by helping our customers
significantly expand and accelerate their multi-omics efforts,”
said Glenn Bilawsky, CEO of Discovery Life Sciences. “Rapid
acquisition of data speeds development. This Consortium will
provide new, highly-scaled and more comprehensive capabilities to
develop and deploy novel biomarkers, drug candidates, and
diagnostics.”
“We are entering a new era where progress is expected at
pandemic speed. This collaboration and its commitment to
proteogenomic accessibility will help accelerate many new
discoveries for disease research. Sensitive detection and robust
quantitation of biomarkers are foundational to Precision Medicine,
and support earlier and better diagnosis, along with more
personalized and effective treatments,” said Joe Fox, President at
SCIEX.
“We are thrilled to collaborate with Discovery Life Sciences and
SCIEX to bring unbiased, deep proteogenomics at scale to the
market,” said Omid Farokhzad, CEO and Founder at Seer. “Through our
collaboration, we will empower genomics researchers to add
unbiased, deep proteomics data to their studies, connecting
genotype to phenotype, and enabling multi-omic studies of
unprecedented resolution.”
The Proteogenomics Consortium aims to significantly expand our
understanding of the proteome in an unbiased manner across a
variety of cohorts and disease states. With a phased approach to
building a 100,000 sample per-year capacity, the Proteogenomics
Consortium plans to create the workflows and expertise to run
large-scale proteogenomic projects efficiently, quickly, and
robustly. Through the Consortium there is also an opportunity for
future collaborations to further pave the way for adoption of
proteogenomics via workflow optimization and joint
publications.
About Discovery Life Sciences
Discovery Life Sciences is the global market leader in
Biospecimen analysis, procurement, distribution, and Biomarker
Services for the pharmaceutical, biotechnology, and diagnostics
industries. HudsonAlpha Discovery is Discovery’s globally
recognized sequencing and bioinformatics division that leverages
the most current short- and long-read genomic analysis technologies
to support discovery, translational, and clinical research
comprehensively. Driven by science, the Discovery team engages with
customers in an innovative, consultative approach to support the
rapid acquisition and analysis of data to support decision making
and the deployment of new innovations. We are Science at your
Service™. For more information, visit dls.com.
About SCIEX
SCIEX delivers solutions for the precision detection and
quantification of molecules, empowering our customers to protect
and advance the wellness and safety of all. We have been at the
forefront of the field of mass spectrometry for 50 years. From the
launch of the first ever commercially successful triple quadrupole
in 1981, we have developed groundbreaking technologies and
solutions that influence life-changing research and outcomes.
Today, we continue to pioneer robust solutions in mass
spectrometry and capillary electrophoresis. Our customers are able
to quickly respond to environmental hazards, better understand
biomarkers relevant to disease, improve patient care in the clinic,
bring relevant drugs to market faster and keep food healthier and
safer.
That’s why thousands of life science experts around the world
choose SCIEX to get the answers they can trust to better inform
critical decisions that positively impact lives.
For more information, please visit sciex.com
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that
includes proprietary engineered nanoparticles, consumables,
automation instrumentation and software to perform deep, unbiased
proteomic analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding Seer’s ability to
successfully execute the development and commercialization of its
Proteograph or the combined solution offered by the Consortium
agreement, the capacity to analyze and catalog more than one
billion peptides each year, the discovery of new protein variants,
novel biomarkers leading to therapeutic breakthroughs, the
ability of the combined product offering to enable labs to perform
unbiased, deep proteomics studies at scale to deliver new levels of
insight, speed, and sensitivity, to expand unbiased proteomics
discovery efforts, expand application sets, and future
collaborations. These and other risks are described more fully in
Seer’s filings with the Securities and Exchange Commission (“SEC”)
and other documents that Seer subsequently files with the SEC from
time to time. Except to the extent required by law, Seer undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
Seer Media Contact:
pr@seer.bio
Discovery Life Sciences Media Contact:
discovery.communications@dls.com
Sciex Media Contact:
Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media
lulu.vanzandt@sciex.com
M: +1 (508) 782-9484
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024